Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603386 | 1.00 | RAB9A (0.36) | RAB9AKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6603388 | 1.00 | RAB9A (0.36) | RAB9AKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6602859 | 0.94 | SMN1; SMN2 (0.38) | RAB9AKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6602867 | 0.94 | SMN1; SMN2 (0.38) | RAB9AKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6602871 | 0.94 | SMN1; SMN2 (0.38) | RAB9AKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6601584 | 0.89 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL6601578 | 0.89 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL6601571 | 0.89 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL6600000 | 0.87 | NPSR1 (0.34) | ALDH1A1TSHR | |
| SCHEMBL6599995 | 0.87 | NPSR1 (0.34) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794523-B2 | ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| EP-0667772-B9 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIV FLORIDA STATE (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | FLORIDA STATE UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| EP-0667772-B1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIV FLORIDA STATE (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | FLORIDA STATE UNIVERSITY | 2003-04-03 | — | — | US | disclosed |
| US-6521660-B2 | Anticancer, antitumor agents | FLORIDA STATE UNIVERSITY | 2003-02-18 | — | — | US | disclosed |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY | 2002-10-10 | — | — | US | disclosed |
| US-6335362-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS FOR LEUKEMIA | FLORIDA STATE UNIVERSITY | 2002-01-01 | — | — | US | disclosed |
| US-6018073-A | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5739362-A | ANTILEUKEMIA, ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | MCL1, BCL3, TOP2A | RAB9A 2180/4885KMT2A 1890/4885MEN1 2533/4885 |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | MCL1, TP53, EWSR1 | RAB9A 2687/4885KMT2A 574/4885MEN1 959/4885 |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | TOP2A, TOP2B, TUBB3 | RAB9A 2555/4885KMT2A 2652/4885MEN1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.